EpiVax Raised $2M Funding from the US FDA for Immunogenicity Testing of Biosimilars
Shots:
- The US FDA has awarded the company a $2M grant over 2yrs. for investigating the immunogenicity of biosimilars
- To enhance the development of biosimilar candidates and evaluate the interchangeability of biosimilars, the analyses will validate a method for immunogenicity risk assessment of host cell proteins (HCPs)
- The funding will help EpiVax to assess in silico tools for screening and triaging HCPs to induce an unwanted immune response in patients receiving a biosimilar. The preclinical validation of in silico tools improved the safety of biological drugs and accelerates the assessment process of immunogenicity risk for biosimilars
Ref: PR Newswire | Image: Epivax
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
